Independent Researcher, Westborough, Massachusetts.
Andrologia. 2019 Nov;51(10):e13388. doi: 10.1111/and.13388. Epub 2019 Sep 2.
Studies assessing the efficacy of intralesional verapamil injection in the treatment of Peyronie's disease have yielded mixed results. The purpose of this meta-analysis is to systematise the existing literature on the efficacy of intralesional verapamil injection when used in the treatment of Peyronie's disease. The treatment outcomes of seven different study groups identified by computerised literature search were compared with natural history outcomes and data from control groups of three studies involving placebo saline injection. An exploratory meta-analysis was performed on the data due to differing patient populations, treatment protocols, and inconsistent selection and reporting of outcomes. Intralesional verapamil injection significantly improved sexual function (p < .0005) and penile curvature (p < .005) in individuals with Peyronie's disease. Decreases in pain may be significant after therapy but are questionable. The effect of verapamil on plaque size remains less impressive (p > .05). Intralesional verapamil injection has promise to positively impact a number of clinical outcomes of Peyronie's disease; however, a large, multicentre, randomised, controlled study with reliable protocols is needed to confirm the efficacy of treatment.
研究评估了腔内维拉帕米注射治疗 Peyronie 病的疗效，结果喜忧参半。本荟萃分析的目的是系统地总结现有的关于腔内维拉帕米注射治疗 Peyronie 病疗效的文献。通过计算机文献检索确定的七个不同研究组的治疗结果与自然病史结果和涉及安慰剂生理盐水注射的三项研究的对照组数据进行了比较。由于患者人群、治疗方案以及结局的选择和报告不一致，对数据进行了探索性荟萃分析。腔内维拉帕米注射可显著改善 Peyronie 病患者的性功能（p<.0005）和阴茎弯曲度（p<.005）。治疗后疼痛可能会明显减轻，但值得怀疑。维拉帕米对斑块大小的影响仍然不明显（p>.05）。腔内维拉帕米注射有希望对 Peyronie 病的许多临床结局产生积极影响；然而，需要进行大型、多中心、随机、对照研究，制定可靠的方案，以确认治疗效果。
